Mozart Therapeutics is focused on developing innovative therapies aimed at restoring healthy immune system function in patients suffering from autoimmune diseases. The company is pioneering first-in-class CD8 Treg modulators, which target the underlying causes of immune dysregulation. These modulators are designed to enhance the functionality of regulatory CD8 T cells (CD8 Treg), which play a crucial role in maintaining immune homeostasis by controlling pathogenic immune responses. By addressing CD8 Treg dysfunction, which is often exacerbated by the presence of inhibitory killer immunoglobulin-like receptors (KIR), Mozart aims to prevent the expansion of pathogenic CD4 T cells and the subsequent inflammatory cascade that leads to tissue damage.

The company's pipeline includes two primary products: MTX-101 and MTX-201, both of which are bispecific antibodies designed to modulate CD8 Treg activity. MTX-101 targets both KIR and CD8 receptors to selectively activate CD8 Treg, making it suitable for early-stage autoimmune diseases like type 1 diabetes and celiac disease. Meanwhile, MTX-201 focuses on inhibiting KIR and activating the ICOS costimulatory receptor to enhance CD8 Treg functionality, particularly in highly inflammatory conditions such as inflammatory bowel diseases. Through these targeted approaches, Mozart Therapeutics aims to provide durable control of autoimmune diseases by restoring the intrinsic functions of CD8 Treg and preventing downstream inflammation.

United States

Mozart is developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory immune pathway.

Mozart Therapeutics

Company Details